Leucine

Leucine

SCHEMBL1786606

CC(C)C[C@H](N)C(=O)O.C[C@H](N)C(=O)O.O=C(O)[C@@H]1CCCN1

nearest known ligand 0.51

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

SLC5A2

The experimentally established mechanism targets of Leucine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
SLC7A5 Q01650 1/20 0.51
SLC1A3 P43003 3/20 0.42
SLC1A2 P43004 3/20 0.42
SLC1A1 P43005 2/20 0.37
DPP4 P27487 3/20 0.35
DPP8 Q6V1X1 1/20 0.35
DPP9 Q86TI2 1/20 0.35
DPP7 Q9UHL4 1/20 0.35
NOS2 P35228 2/20 0.34
NOS3 P29474 1/20 0.34
NOS1 P29475 1/20 0.34
PRCP P42785 1/20 0.34
GRIK1 P39086 1/20 0.33
GRIA2 P42262 1/20 0.33
GRIA4 P48058 1/20 0.33
GRIK3 Q13003 1/20 0.33
GRIK5 Q16478 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Leucine SCHEMBL8817376 1.00 SLC7A5 (0.51) SLC7A5SLC1A3SLC1A2SLC1A1DPP4
Leucine SCHEMBL17113855 0.97 SLC7A5 (0.55) SLC7A5SLC1A3SLC1A2SLC1A1DPP4
Leucine SCHEMBL5060410 0.97 SLC7A5 (0.55) SLC7A5SLC1A3SLC1A2SLC1A1DPP4
Leucine SCHEMBL29092653 0.97 SLC7A5 (0.55) SLC7A5SLC1A3SLC1A2SLC1A1DPP4
D-Leucine SCHEMBL1537225 0.97 SLC7A5 (0.55) SLC7A5SLC1A3SLC1A2SLC1A1DPP4
Leucine SCHEMBL139230 0.97 SLC7A5 (0.55) SLC7A5SLC1A3SLC1A2SLC1A1DPP4
Leucine SCHEMBL139231 0.97 SLC7A5 (0.55) SLC7A5SLC1A3SLC1A2SLC1A1DPP4
Leucine SCHEMBL17113857 0.97 SLC7A5 (0.55) SLC7A5SLC1A3SLC1A2SLC1A1DPP4
Leucine SCHEMBL756554 0.97 SLC7A5 (0.55) SLC7A5SLC1A3SLC1A2SLC1A1DPP4
Leucine SCHEMBL756553 0.97 SLC7A5 (0.55) SLC7A5SLC1A3SLC1A2SLC1A1DPP4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 42 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3983017-A1 METHODS TO TREAT VIRAL INFECTIONS The Board Of Trustees Of The Leland Stanford Junior University (US) 2022-04-20 EP claimed
CN-114286692-A Methods of treating viral infections 小利兰·斯坦福大学托管委员会 2022-04-05 CN claimed
WO-2020251941-A1 METHODS TO TREAT VIRAL INFECTIONS THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2020-12-17 WO claimed
US-20190033313-A1 METHODS AND SYSTEMS FOR DETECTING MELANOMA UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. 2019-01-31 US claimed
WO-2016196743-A1 METHODS AND SYSTEMS FOR DETECTING MELANOMA THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2016-12-08 WO claimed
WO-2023225654-A1 METHODS AND COMPOSITIONS FOR TREATING OBESITY, OBESITY-RELATED DISEASES, FATTY LIVER AND FATTY LIVER ASSOCIATED DISEASES WITH ANTI-CD24 AGENTS THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2023-11-23 WO disclosed
EP-3983017-A1 METHODS TO TREAT VIRAL INFECTIONS The Board Of Trustees Of The Leland Stanford Junior University (US) 2022-04-20 EP disclosed
CN-114286692-A Methods of treating viral infections 小利兰·斯坦福大学托管委员会 2022-04-05 CN disclosed
WO-2020251941-A1 METHODS TO TREAT VIRAL INFECTIONS THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (US) 2020-12-17 WO disclosed
US-20190033313-A1 METHODS AND SYSTEMS FOR DETECTING MELANOMA UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. 2019-01-31 US disclosed
WO-2016196743-A1 METHODS AND SYSTEMS FOR DETECTING MELANOMA THE UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) 2016-12-08 WO disclosed
US-8614301-B2 Methods of treating cancer using anti CD24 antibodies The Medical Research, Infrastructure and Health Services Fund of the Tel Aviv Medical Center (IL) 2013-12-24 US disclosed
EP-2222697-A2 IMMUNOSUPPRESSIVE POLYPEPTIDES AND NUCLEIC ACIDS Perseid Therapeutics LLC (US) 2010-09-01 EP disclosed
EP-2209492-A1 METHODS OF TREATING CANCER USING ANTI CD24 ANTIBODIES The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center (IL) 2010-07-28 EP disclosed
US-20090258031-A1 IMMUNOSUPPRESSIVE POLYPEPTIDES AND NUCLEIC ACIDS MAXYGEN, INC. (US) 2009-10-15 US disclosed
WO-2009063461-A1 METHODS OF TREATING CANCER USING ANTI CD24 ANTIBODIES THE MEDICAL RESEARCH, INFRASTRUCTURE, AND HEALTH SERVICES FUND OF THE TEL AVIV MEDICAL CENTER (IL) 2009-05-22 WO disclosed
WO-2009058564-A2 IMMUNOSUPPRESSIVE POLYPEPTIDES AND NUCLEIC ACIDS MAXYGEN, INC. (US) 2009-05-07 WO disclosed
US-5952471-A ANTIBODY THAT BINDS TO EPITOPE CONTAINING VALINE AMINO ACID; DIAGNOSIS; ANTICARCINOGENIC AGENTS CELLTECH THERAPEUTICS LIMITED (GB) 1999-09-14 US disclosed
WO-1997014795-A1 TUMOR ASSOCIATED POLYPEPTIDES WITH CARBOXYL-TERMINAL ALANINE-PROLINE, PROLINE-PROLINE OR GLYCINE-PROLINE AND ANTIBODIES THERETO JOHN WAYNE CANCER INSTITUTE (US) 1997-04-24 WO disclosed
WO-1996004312-A1 SMALL CELL LUNG CARCINOMA PEPTIDES AND BINDING AGENTS CELLTECH THERAPEUTICS LIMITED (GB) 1996-02-15 WO disclosed